Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Neurotech Pharmaceuticals, Inc.

News headline image
Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Neurotech Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
First FDA-Approved Treatment for MacTel Performed
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Neurotech Appoints Beth Marsh as Chief Commercial Officer
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel)
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alex Gorsky Joins Neurotech’s Board as Lead Director
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Neurotech Pharmaceuticals, Inc. Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
News headline image
Neurotech Pharmaceuticals Appoints Thomas Aaberg Jr., M.D. as Chief Medical Officer
From Neurotech Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.